ERBB2 and ductal breast carcinoma in situ: In our study, many patients were at high-risk: 91.1% (n = 72) patients had invasive ductal carcinomas (IDC) or IDC + ductal carcinoma in situ (DCIS); 11.4% (n = 9) were grade 3; 20.3% (n = 16) were human epidermal growth factor receptor type 2(HER2)-positive; 41.2% (n = 33) had axillary node invasion; and 13.9% (n = 11) were stage III or IV at diagnosis.